This has been such a wild, volatile week for the markets.
If you are an active trader like me, you’re probably ready for a nice break this weekend spend some time not watching red and green lines zoom up and down.
Well, don’t check out just yet!
We have a beautiful market recovery this morning, and I think there is a great opportunity to strike one more time.
Last night, I mentioned there was a specific stock I was eyeing closely, and I think it has incredible potential today.
Go to your favorite platform and pull up Silo Pharma Inc. (SILO) right now, and you’ll see why I like this stock so much today.
If you’ve been paying attention to my alerts, you’ll remember this one from last month.
I was pounding the table for you to look at it at $1 when the daily trading range was very “tight” for several weeks.
Well, if you look at the chart below, you’ll see that led to one of the best performing (maybe the best?) stocks over the last few weeks.
A few days after my last alert, you can see SILO made a move over 300% higher!
This is just a weird trading phenomenon. I can’t really tell you I understand it 100%, but my guess is that when you have a stock with a low float and high short interest, the market just does crazy things sometimes (it can go in either direction, btw)
Many traders would refer to that move as a “squeeze,” which I think perfectly describes it.
Right now, I would say SILO has everything I am looking for before a big potential move, though again, it could be in either direction, so always be prepared.
I think if SILO can break above the $2.30 range that has pinned it lower over the last few days, we could see a nice breakout.
If it moves to the upside, I can’t even guess how high it could go?
Just look at the previous moves and judge for yourself.
On the downside, I would protect myself under $2. If it looks like the stock will close below there, I would personally take a loss and move on.
Of course, I will never tell you what to do with a trade; these are simply my personal opinions as a 20-year trading veteran. Everyone needs to have their own game plan.
SILO could be setting up for a powerful close to end the week – make sure you get it on your radar right away this morning.
I don’t want you to miss a single opportunity today!
As always, spend some time doing your homework on this and see what you think about it. I’ll get you started with some notes I put together after reading more about them…
Silo Pharma Inc. (SILO) is a developmental-stage biopharma company developing novel treatments for conditions such as PTSD, stress-induced psychiatric disorders, chronic pain conditions, and fibromyalgia.
The company is especially focused on psychedelic-based compounds and has partnered with leading institutions such as Columbia University and the University of Maryland, Baltimore.
By partnering with these institutions, the company hopes to use the FDA’s streamlined and lower-cost 505(b)(2) pathway for drug approval, which allows the inclusion of external safety and efficacy data in Investigational New Drug (IND) applications.
All the therapeutics in SILO’s pipeline are in the preclinical phase, but its leading candidate is SPC-15, which targets stress-induced affective disorders such as anxiety and PTSD.
SPC-15 is being developed under a 2021 sponsored research agreement with Columbia University, which gave SILO the option to exclusively license SPC-15 for further development, manufacture, and commercialization.
SILO exercised that option earlier this month, in what CEO Eric Weisblum called a “critical step” for the company that “could increase shareholder value in the future.”
SPC-15 is an intranasal prophylactic treatment for PTSD that the company intends for military personnel, first responders, and others at high risk of the condition.
In June, SILO announced its submission of a pre-Investigational New Drug (pre-IND) briefing package and meeting request to the FDA for SPC-15, noting its positive results from a small animal dose-ranging study completed in February.
SILO’s next prioritized program is SP-26, which is an injectable, time-release ketamine-loaded implant for treatment of chronic pain, especially pain related to fibromyalgia.
According to the company, SP-26 “holds the potential to be the first at-home ketamine treatment approved for chronic pain management.”
On June 7, SILO revealed positive production news about the implant.
Mr. Weisblum said, “The results so far in our ongoing SP-26 pre-clinical research bring us closer to determining the optimal formulation for future pre-clinical testing models.”
A third program is SP-14, which is a novel therapeutic also developed by Columbia University that targets Alzheimer’s.
Preclinical testing and proof-of-concept is being led by investor Dr. Christine Denny of Columbia.
This intranasal, ketamine-related therapeutic has been found to reduce anxiety in animal studies.
Last Tuesday, July 16, SILO announced that it had exercised its option to license SP-14 from Columbia.
Lastly, in partnership with the University of Maryland, Baltimore, SILO is developing SPU-16, a patented peptide that targets the central nervous system for potential treatment of multiple sclerosis.
Spend time right now doing your own research on the stock, and of course, always approach your trading in a responsible manner. Trading is very risky, and nothing is ever guaranteed, so never trade with more than you can afford to lose. Please read the full disclaimer at the bottom of this email as well so you are aware of additional risks and considerations. Always have a well-thought-out game plan that takes your personal risk tolerance into consideration.
Bottom line: Historically, this is a very volatile and fast-moving stock, so be prepared for that today. I am expecting a lot of wild action, and if I’m lucky, maybe a move similar to what it made previously.
Tons of traders are going to watch SILO soon. Make sure it is on your radar NOW!
To Your Success,
Jeff Bishop
P.S. Make sure you join me and over 1000 traders in the Market Master’s trading room today for live trading signals and education. You can access it at no cost right now.
👊 Make sure you are getting my mobile text alerts – text “RAGE” to 1-(888) 404-5747 to get all of my latest HOT STOCK ideas delivered right to your phone (make sure you put the “1” at the front!). Don’t miss out!
*Just so you know, what you’re reading is curated content for which we have received a monetary fee (detailed below) to create and distribute. Let’s be clear that investing can be quite the roller coaster as stock prices can have wild swings up and down, so consider those crucial risks before you ever consider trading anything we discuss. Make sure you check out our full disclosure down below for the details on how we were paid, the risks, and why these results aren’t what you’d call “typical.”
Just a quick heads up about this ad you’re reading—as we’ve said, even though we like the company referenced above, and all the facts we discussed above are true to the best of our knowledge, we are running a business here. To distribute this information and help offset the costs of maintaining our large digital audience, in advance of writing the content above, we received fifteen thousand dollars (cash) from Sica Media for advertising Silo Pharma, Inc for a one day marketing program on July 26, 2024. Previously, we received fifteen thousand dollars (cash) from Sica Media for advertising Silo Pharma, Inc for a one day marketing program on June 13, 2024. These amounts were paid by someone else not connected to Silo Pharma, Inc. It might be obvious, but whoever paid for this might own shares and is likely looking to sell some or all of them at any time after we send out this information, which might affect the stock price. We may also buy or sell shares in the company at some point in the future, although neither RagingBull nor its owners own any shares of the company at this time. Also, keep in mind that due to the sheer size of our audience, if even a small percentage of people decide they want to buy this stock, it could potentially boost interest enough to hike up those share prices and cause a temporary spike, and the opposite is possible as our program ends, though that is not always the case.
Now, diving right into Silo Pharma, Inc might sound exciting. But remember, it’s like venturing into the wilderness—be aware that there’s exceptional risk involved in trading. This isn’t small potatoes we’re talking about; you could lose every dime you put in, so always carefully think about what you’re doing. That’s why they call this trading, after all. We’re shining a light on the good stuff about the company here, but it’s on you to do your homework, make your own calls, and determine a plan for your own trading, hopefully with the help of your professional 1nvestment advis0r.
Oh, that brings us to another crucial point—we’re not here to tell you (or even recommend) what you should do with your hard-earned money. We’re simply sharing our non-expert thoughts by highlighting some companies we like that could use some help telling their story to more people. We’re obviously biased in our writing. We’re not here to dig into anything that may be negative about the company; this is advertising, after all! Also, keep in mind that if we make some predictions about the future, these are technically known as “forward-L00king statements” under the securities acts, so take those with a grain of salt. As with all forecasts, they’re not set in stone, often wrong, and we certainly can’t know where the Company’s earnings, business, or share price will be tomorrow or a year from now.
Everything you read from us is all for your education, information, and possible entertainment. While we believe the info is reliable and accurate, we can’t wear a cape and guarantee it. Before you jump into anything, make sure to talk it over with a pro—someone you trust who’s licensed to give you real advice. To be clear,
Neither Raging Bull nor its owners, employees, or independent contractors are registered as a secur1ties br0ker-dealer, br0ker, 1nvestment advis0r (IA), or IA rep’s with the SEC, any state securities regulat0ry authority, or any self-regulat0ry organization.
So, that’s the scoop! If you’re intrigued and want to learn more about the companies we talk about, hit up the SEC’s website to dig into their filings and see the full picture.